Compare AbbVie Inc (ABBV) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? AbbVie Inc trades at $253.48 (market cap $449.91B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | VNQI | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $50.76 |
52-Week Low | $184.85 | $43.26 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.50, up 0.38% with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF offers international real estate diversification with a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent news highlights its cost advantage over competitors and institutional buying interest from Eagle Bay Advisors, which increased its stake by 95.7% in Q4 2025.
VNQI presents a compelling opportunity for yield-seeking investors seeking global real estate exposure at low cost, with recovery potential as global transaction volumes are expected to rise over 10% in 2026. Key risks include currency fluctuations, international economic volatility, and interest rate sensitivity. The ETF's valuation appears reasonable at 11.9x P/E and 0.9x P/B according to Seeking Alpha analysis from May 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
